Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

BMRN

BIOMARIN PHARMACEUTICAL INC

Pharmaceutical Preparations · SIC 2834CIK 1048477Held by 10 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$3.22B
Net Income FY2025
$0.35B
EPS (Basic, as reported)
$1.82
Net Margin FY2025
10.8%
ROE FY2025
5.7%
Total Equity
$6.09B
Shares Out
194M
Business description

BIOMARIN PHARMACEUTICAL INC — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2008–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 1,117 → 3,221 +12.5% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1,1171,3141,4911,7041,8601,8462,0962,4192,8543,221
Cost of revenue(210)(242)(315)(359)(524)(471)(484)(515)(580)(717)
Research & development(662)(611)(696)(715)(628)(629)(650)(747)(747)(922)
Selling, general & administrative(477)(554)(604)(681)(738)(759)(854)(937)(1,009)(1,153)
Total operating expenses(1,920)(1,328)(1,615)(1,805)(1,897)(1,929)(1,946)(2,261)(2,370)(2,812)
Operating income(803)(15)(124)(100)(37)(82)150158484409
Interest expense(39)(43)(44)(23)(29)(15)(16)(17)(13)(11)
Interest & investment income7152323171018587575
Pre-tax income(831)(36)(143)(95)(42)(75)150189542482
Income tax expense(201)(81)(65)(71)(901)(11)(8)(21)(115)(134)
Net income(630)(117)(77)(24)859(64)142168427349
EPS — basic($3.80)($0.67)($0.44)($0.13)$4.75($0.35)$0.76$0.89$2.25$1.82
EPS — diluted($3.81)($0.67)($0.44)($0.13)$4.53($0.35)$0.75$0.87$2.21$1.80
Shares outstanding — basic (M)166174177179181183185188190192
Shares outstanding — diluted (M)166174177179192183189192197197

Showing the latest 10 of 18 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.